IL13RA2 and glioblastoma: Multi-targeting of Her2, IL-13 receptor subunit alpha-2 (IL13Rα2), and ephrin-A2 (EphA2) was shown to overcome antigenic heterogeneity in 15 primary GBM samples and to increase the therapeutic success using xenograft models (584).